{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:36:22Z","timestamp":1783485382208,"version":"3.55.0"},"reference-count":16,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:p>OBJECTIVE: To evaluate 131I therapy in elderly patients with subclinical hyperthyroidism (SCH) due to nodular disease and who did not receive antithyroid drugs (ATDs), and the effect of the treatment on bone metabolism. SUBJECTS AND METHODS: Thirty-six patients with TSH \u2264 0.1 mIU\/L and non-voluminous goiter (&lt; 60 cm\u00b3) were studied. Bone mineral density (BMD) was assessed in 17 women with osteopenia. RESULTS: Mean 24-h 131I uptake was 17.5%. Symptoms of thyrotoxicosis were reported by two (5.5%) patients in the first week after therapy. One year after radioiodine treatment, SCH was resolved in 30 (83.3%) patients, and hypothyroidism was detected in one (2.7%). In the patients in whom TSH returned to normal, femoral and lumbar spine BMD increased by 1.9% and 1.6%, respectively, in average. CONCLUSIONS: In elderly patients with SCH and non-voluminous goiter, radioiodine not preceded by ATDs is a safe and effective therapeutic alternative. Resolution of SCH has beneficial effects on BMD in postmenopausal women with osteopenia.<\/jats:p>","DOI":"10.1590\/s0004-27302013000200008","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T05:07:36Z","timestamp":1363842456000},"page":"144-147","source":"Crossref","is-referenced-by-count":17,"title":["Radioiodine therapy in elderly patients with subclinical hyperthyroidism due to non-voluminous nodular goiter and its effect on bone metabolism"],"prefix":"10.1590","volume":"57","author":[{"given":"Pedro Weslley","family":"Rosario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/thy.2010.0417","article-title":"Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists","volume":"21","author":"Bahn Chair RS","year":"2011","journal-title":"Thyroid."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2265.2009.03696.x","article-title":"Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU\/l: a prospective study","volume":"72","author":"Rosario PW","year":"2010","journal-title":"Clin Endocrinol (Oxf)."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1530\/eje.0.1390587","article-title":"Relationship between serum TSH and the responsiveness of toxic solitary autonomous thyroid nodules to radioiodine therapy","volume":"139","author":"Pedersen-Bjergaard U","year":"1998","journal-title":"Eur J Endocrinol."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1530\/eje.0.1370365","article-title":"Serum TSH and the response to radioiodine treatment of toxic multinodular goitre","volume":"137","author":"Pedersen-Bjergaard U","year":"1997","journal-title":"Eur J Endocrinol."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/bmj.39114.670150.BE","article-title":"Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials","volume":"334","author":"Walter MA","year":"2007","journal-title":"BMJ."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1590\/S0004-27302008000900007","article-title":"Bone and heart abnormalities of subclinical hyperthyroidism in women below the age of 65 years","volume":"52","author":"Rosario PW","year":"2008","journal-title":"Arq Bras Endocrinol Metabol."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2265.1994.tb02571.x","article-title":"Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism","volume":"41","author":"Muddle AH","year":"1994","journal-title":"Clin Endocrinol (Oxf)."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2265.1998.00427.x","article-title":"Normalization of serum thyrotropin by mean of radioiodine treatment in subclinical hyperthyroidism: effect of bone loss in postmenopausal women","volume":"48","author":"Faber J","year":"1998","journal-title":"Clin Endocrinol (Oxf)."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1507\/endocrj.49.307","article-title":"Is antithyroid treatment really relevant for young patients with subclinical hyperthyroidism?","volume":"49","author":"Yonem O","year":"2002","journal-title":"Endocr J."},{"key":"ref10","first-page":"3611","article-title":"Radioiodine treatment of hyperthyroidism-prognostic factors for outcome","volume":"86","author":"Allahabadia A","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archinte.1988.00380020131018","article-title":"Symptom rating scale for assessing hyperthyroidism","volume":"148","author":"Klein I","year":"1988","journal-title":"Arch Intern Med."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1210\/jc.2011-2218","article-title":"IOM committee members respond to Endocrine Society vitamin D guideline","volume":"97","author":"Rosen CJ","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1210\/jc.2011-0090","article-title":"Clinical Review: The 2011 report on dietary reference intake for vitamin D: where do we go from here?","volume":"96","author":"Aloia JF","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"ref14","first-page":"1073","article-title":"High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease","volume":"87","author":"Alexander EK","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"ref15","first-page":"3488","article-title":"The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study","volume":"86","author":"Andrade VA","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1210\/jc.2011-3335","article-title":"Prestimulation with Recombinant Human Thyrotropin (rhTSH) improves the long-term outcome of radioiodine therapy for multinodular nontoxic goiter","volume":"97","author":"Fast S","year":"2012","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v57n2\/08.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T12:13:47Z","timestamp":1495887227000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302013000200008&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0004-27302013000200008"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302013000200008","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}